公众号 / 文章胸部CTPET

病例286:类结节病肉芽肿病与淋巴结病——纳武利尤单抗药物毒性的胸部表现

Case 286: Sarcoidlike Granulomatosis and Lymphadenopathy-Thoracic Manifestations of Nivolumab Drug Toxicity.
PubMed 文献 · Radiology · 2021-01-01

70岁男性黑色素瘤患者,纳武利尤单抗治疗5个月后首次随访胸部CT显示纵隔及双肺新发表现,患者无症状,皮下转移灶稳定。本文为病例报告,展示纳武利尤单抗药物毒性所致类结节病肉芽肿病与淋巴结病的胸部影像表现。

要点

  • 纳武利尤单抗治疗后可出现类结节病肉芽肿病与淋巴结病的胸部影像表现,患者可无症状。
  • 本例在治疗5个月后首次随访胸部CT显示纵隔及双肺新发表现。
  • 皮下转移病灶在治疗期间保持稳定,未见其他部位转移。

核心结论

  • 纳武利尤单抗治疗5个月后首次随访胸部CT显示纵隔及双肺新发表现,患者无症状,皮下转移病灶稳定。

研究设计与样本

  • 病例报告(Case 286),患者为70岁男性黑色素瘤患者,接受纳武利尤单抗治疗。

关键影像表现/征象

  • 基线(纳武利尤单抗开始前)CT未见提示转移性疾病的征象,纵隔或肺门淋巴结无增大。
  • 纳武利尤单抗开始5个月后首次随访胸部CT显示纵隔及双肺新发表现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

History A 70-year-old man had a posterior left thigh lesion confirmed to be biopsy-proven melanoma. The patient underwent wide excision and sentinel node biopsy, which showed absence of residual melanoma. Two years later, the patient noticed a subcentimeter subcutaneous lump in his thigh. Repeat excisional biopsy showed involvement of the surrounding soft tissue, consistent with a satellite lesion. Follow-up combined PET/CT revealed satellite nodules around the primary lesion, enabling confirmation of subcutaneous metastatic disease. The patient was subsequently started on nivolumab, an anti-programmed cell death 1 (PD-1) immune checkpoint inhibitor that blocks PD-1 and is approved as a first-line treatment in patients with advanced metastatic melanoma. On the baseline scan prior to starting nivolumab, there were no CT findings that suggested metastatic disease, nor were there enlarged mediastinal or hilar lymph nodes. Five months after initiation of nivolumab treatment, the first follow-up chest CT scan was performed and showed new findings in the mediastinum and bilateral lungs. The patient remained asymptomatic during the treatment period. Furthermore, the subcutaneous metastatic disease remained stable during the treatment period, and no other site of metastatic disease was noted on follow-up CT scans obtained during the first 5 months of treatment. The patient had no prior history of infectious or occupational exposures. During the nivolumab treatment cycle, his pertinent laboratory values and physical examination findings were unremarkable.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Chiang J, Hebroni F, Bedayat A, et al. Case 286: Sarcoidlike Granulomatosis and Lymphadenopathy-Thoracic Manifestations of Nivolumab Drug Toxicity. Radiology. 2021. PMID: 33493088. doi:10.1148/radiol.2021191247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。